<!DOCTYPE html><html lang="en" ><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta name="theme-color" media="(prefers-color-scheme: light)" content="#f7f7f7"><meta name="theme-color" media="(prefers-color-scheme: dark)" content="#1b1b1e"><meta name="apple-mobile-web-app-capable" content="yes"><meta name="apple-mobile-web-app-status-bar-style" content="black-translucent"><meta name="viewport" content="width=device-width, user-scalable=no initial-scale=1, shrink-to-fit=no, viewport-fit=cover" ><meta name="generator" content="Jekyll v4.3.2" /><meta property="og:title" content="EGFR Targeted Fluorescence Imaging in Gliomas" /><meta property="og:locale" content="en" /><meta name="description" content="Glioblastomas are among the most common malignancies of the brain, with a median survival time of &lt;18 months after initial diagnosis. These tumors are highly invasive in nature and typically infiltrate along the white matter tracts. Anatomic imaging modalities including contrast-enhanced computed tomography and magnetic resonance imaging (MRI) are used extensively for the diagnosis of intracranial neoplasms. However, infiltrative tumor cells (beyond the areas of contrast enhancement) and certain pediatric brain tumors grow in a diffused pattern and do not exhibit contrast enhancement, thereby limiting the use of these imaging modalities. Over the past several years, advanced imaging methods that probe tumor metabolism (magnetic resonance spectroscopy ) or neovascularity (cerebral blood volume ) have been added to clinical imaging routines for increasing the diagnostic efficacy. However, these methods suffer from relatively poor sensitivity and lack the specificity of detecting changes at cellular level. Molecular MRI techniques using targeted contrast agents have recently been proposed to specifically target the tumor cells (see Delikatny and Poptani and references therein). However, these methods are still in their infancy and are limited to poor sensitivity inherent to MRI methods." /><meta property="og:description" content="Glioblastomas are among the most common malignancies of the brain, with a median survival time of &lt;18 months after initial diagnosis. These tumors are highly invasive in nature and typically infiltrate along the white matter tracts. Anatomic imaging modalities including contrast-enhanced computed tomography and magnetic resonance imaging (MRI) are used extensively for the diagnosis of intracranial neoplasms. However, infiltrative tumor cells (beyond the areas of contrast enhancement) and certain pediatric brain tumors grow in a diffused pattern and do not exhibit contrast enhancement, thereby limiting the use of these imaging modalities. Over the past several years, advanced imaging methods that probe tumor metabolism (magnetic resonance spectroscopy ) or neovascularity (cerebral blood volume ) have been added to clinical imaging routines for increasing the diagnostic efficacy. However, these methods suffer from relatively poor sensitivity and lack the specificity of detecting changes at cellular level. Molecular MRI techniques using targeted contrast agents have recently been proposed to specifically target the tumor cells (see Delikatny and Poptani and references therein). However, these methods are still in their infancy and are limited to poor sensitivity inherent to MRI methods." /><link rel="canonical" href="https://clinicaltree.github.io/posts/egfr-targeted-fluorescence-imaging-in-gliomas/" /><meta property="og:url" content="https://clinicaltree.github.io/posts/egfr-targeted-fluorescence-imaging-in-gliomas/" /><meta property="og:site_name" content="Radiology Tree" /><meta property="og:type" content="article" /><meta property="article:published_time" content="2009-12-31T17:00:00+00:00" /><meta name="twitter:card" content="summary" /><meta property="twitter:title" content="EGFR Targeted Fluorescence Imaging in Gliomas" /><meta name="twitter:site" content="@twitter_username" /><meta name="google-site-verification" content="RFHVRgQqK0eGjftEMCTDhsDrR8cJ_ZYcfCX52gXW8KM" /> <script type="application/ld+json"> {"@context":"https://schema.org","@type":"BlogPosting","dateModified":"2023-04-07T07:15:32+00:00","datePublished":"2009-12-31T17:00:00+00:00","description":"Glioblastomas are among the most common malignancies of the brain, with a median survival time of &lt;18 months after initial diagnosis. These tumors are highly invasive in nature and typically infiltrate along the white matter tracts. Anatomic imaging modalities including contrast-enhanced computed tomography and magnetic resonance imaging (MRI) are used extensively for the diagnosis of intracranial neoplasms. However, infiltrative tumor cells (beyond the areas of contrast enhancement) and certain pediatric brain tumors grow in a diffused pattern and do not exhibit contrast enhancement, thereby limiting the use of these imaging modalities. Over the past several years, advanced imaging methods that probe tumor metabolism (magnetic resonance spectroscopy ) or neovascularity (cerebral blood volume ) have been added to clinical imaging routines for increasing the diagnostic efficacy. However, these methods suffer from relatively poor sensitivity and lack the specificity of detecting changes at cellular level. Molecular MRI techniques using targeted contrast agents have recently been proposed to specifically target the tumor cells (see Delikatny and Poptani and references therein). However, these methods are still in their infancy and are limited to poor sensitivity inherent to MRI methods.","headline":"EGFR Targeted Fluorescence Imaging in Gliomas","mainEntityOfPage":{"@type":"WebPage","@id":"https://clinicaltree.github.io/posts/egfr-targeted-fluorescence-imaging-in-gliomas/"},"url":"https://clinicaltree.github.io/posts/egfr-targeted-fluorescence-imaging-in-gliomas/"}</script><title>EGFR Targeted Fluorescence Imaging in Gliomas | Radiology Tree</title><link rel="apple-touch-icon" sizes="180x180" href="/assets/img/favicons/apple-touch-icon.png"><link rel="icon" type="image/png" sizes="32x32" href="/assets/img/favicons/favicon-32x32.png"><link rel="icon" type="image/png" sizes="16x16" href="/assets/img/favicons/favicon-16x16.png"><link rel="manifest" href="/assets/img/favicons/site.webmanifest"><link rel="shortcut icon" href="/assets/img/favicons/favicon.ico"><meta name="apple-mobile-web-app-title" content="Radiology Tree"><meta name="application-name" content="Radiology Tree"><meta name="msapplication-TileColor" content="#da532c"><meta name="msapplication-config" content="/assets/img/favicons/browserconfig.xml"><meta name="theme-color" content="#ffffff"><link rel="preconnect" href="https://fonts.googleapis.com" ><link rel="dns-prefetch" href="https://fonts.googleapis.com" ><link rel="preconnect" href="https://fonts.gstatic.com" crossorigin><link rel="dns-prefetch" href="https://fonts.gstatic.com" crossorigin><link rel="preconnect" href="https://fonts.googleapis.com" ><link rel="dns-prefetch" href="https://fonts.googleapis.com" ><link rel="preconnect" href="https://cdn.jsdelivr.net" ><link rel="dns-prefetch" href="https://cdn.jsdelivr.net" ><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Lato&family=Source+Sans+Pro:wght@400;600;700;900&display=swap"><link rel="preconnect" href="https://www.google-analytics.com" crossorigin="use-credentials"><link rel="dns-prefetch" href="https://www.google-analytics.com"><link rel="preconnect" href="https://www.googletagmanager.com" crossorigin="anonymous"><link rel="dns-prefetch" href="https://www.googletagmanager.com"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/css/bootstrap.min.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/@fortawesome/fontawesome-free@6.2.1/css/all.min.css"><link rel="stylesheet" href="/assets/css/style.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/tocbot@4.20.1/dist/tocbot.min.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/magnific-popup@1.1.0/dist/magnific-popup.min.css"> <script src="https://cdn.jsdelivr.net/npm/jquery@3.6.1/dist/jquery.min.js"></script> <script type="text/javascript"> class ModeToggle { static get MODE_KEY() { return "mode"; } static get MODE_ATTR() { return "data-mode"; } static get DARK_MODE() { return "dark"; } static get LIGHT_MODE() { return "light"; } static get ID() { return "mode-toggle"; } constructor() { if (this.hasMode) { if (this.isDarkMode) { if (!this.isSysDarkPrefer) { this.setDark(); } } else { if (this.isSysDarkPrefer) { this.setLight(); } } } let self = this; /* always follow the system prefers */ this.sysDarkPrefers.addEventListener('change', () => { if (self.hasMode) { if (self.isDarkMode) { if (!self.isSysDarkPrefer) { self.setDark(); } } else { if (self.isSysDarkPrefer) { self.setLight(); } } self.clearMode(); } self.notify(); }); } /* constructor() */ get sysDarkPrefers() { return window.matchMedia("(prefers-color-scheme: dark)"); } get isSysDarkPrefer() { return this.sysDarkPrefers.matches; } get isDarkMode() { return this.mode === ModeToggle.DARK_MODE; } get isLightMode() { return this.mode === ModeToggle.LIGHT_MODE; } get hasMode() { return this.mode != null; } get mode() { return sessionStorage.getItem(ModeToggle.MODE_KEY); } /* get the current mode on screen */ get modeStatus() { if (this.isDarkMode || (!this.hasMode && this.isSysDarkPrefer)) { return ModeToggle.DARK_MODE; } else { return ModeToggle.LIGHT_MODE; } } setDark() { $('html').attr(ModeToggle.MODE_ATTR, ModeToggle.DARK_MODE); sessionStorage.setItem(ModeToggle.MODE_KEY, ModeToggle.DARK_MODE); } setLight() { $('html').attr(ModeToggle.MODE_ATTR, ModeToggle.LIGHT_MODE); sessionStorage.setItem(ModeToggle.MODE_KEY, ModeToggle.LIGHT_MODE); } clearMode() { $('html').removeAttr(ModeToggle.MODE_ATTR); sessionStorage.removeItem(ModeToggle.MODE_KEY); } /* Notify another plugins that the theme mode has changed */ notify() { window.postMessage({ direction: ModeToggle.ID, message: this.modeStatus }, "*"); } flipMode() { if (this.hasMode) { if (this.isSysDarkPrefer) { if (this.isLightMode) { this.clearMode(); } else { this.setLight(); } } else { if (this.isDarkMode) { this.clearMode(); } else { this.setDark(); } } } else { if (this.isSysDarkPrefer) { this.setLight(); } else { this.setDark(); } } this.notify(); } /* flipMode() */ } /* ModeToggle */ const modeToggle = new ModeToggle(); </script><body data-topbar-visible="true"><div id="sidebar" class="d-flex flex-column align-items-end"><div class="profile-wrapper text-center"><div id="avatar"> <a href="/" class="mx-auto"> <img src="https://storage.googleapis.com/clinicalpub.com/images/favicon.png" alt="avatar" onerror="this.style.display='none'"> </a></div><div class="site-title"> <a href="/">Radiology Tree</a></div><div class="site-subtitle font-italic">Update every day the best and the lastest articles, books, journals, clinical cases, videos, images... for radiologist</div></div><ul class="w-100"><li class="nav-item"> <a href="/" class="nav-link"> <i class="fa-fw fas fa-home ml-xl-3 mr-xl-3 unloaded"></i> <span>HOME</span> </a><li class="nav-item"> <a href="/categories/" class="nav-link"> <i class="fa-fw fas fa-stream ml-xl-3 mr-xl-3 unloaded"></i> <span>CATEGORIES</span> </a><li class="nav-item"> <a href="/tags/" class="nav-link"> <i class="fa-fw fas fa-tag ml-xl-3 mr-xl-3 unloaded"></i> <span>TAGS</span> </a><li class="nav-item"> <a href="/archives/" class="nav-link"> <i class="fa-fw fas fa-archive ml-xl-3 mr-xl-3 unloaded"></i> <span>ARCHIVES</span> </a><li class="nav-item"> <a href="/about/" class="nav-link"> <i class="fa-fw fas fa-info-circle ml-xl-3 mr-xl-3 unloaded"></i> <span>ABOUT</span> </a></ul><div class="sidebar-bottom mt-auto d-flex flex-wrap justify-content-center align-items-center"> <button class="mode-toggle btn" aria-label="Switch Mode"> <i class="fas fa-adjust"></i> </button> <span class="icon-border"></span> <a href="https://github.com/clinicaltree" aria-label="github" target="_blank" rel="noopener noreferrer"> <i class="fab fa-github"></i> </a> <a href="https://twitter.com/twitter_username" aria-label="twitter" target="_blank" rel="noopener noreferrer"> <i class="fab fa-twitter"></i> </a> <a href="javascript:location.href = 'mailto:' + ['clinicalpub.team','gmail.com'].join('@')" aria-label="email" > <i class="fas fa-envelope"></i> </a> <a href="/feed.xml" aria-label="rss" > <i class="fas fa-rss"></i> </a></div></div><div id="topbar-wrapper"><div id="topbar" class="container d-flex align-items-center justify-content-between h-100 pl-3 pr-3 pl-md-4 pr-md-4"> <span id="breadcrumb"> <span> <a href="/"> Home </a> </span> <span>EGFR Targeted Fluorescence Imaging in Gliomas</span> </span> <i id="sidebar-trigger" class="fas fa-bars fa-fw"></i><div id="topbar-title"> Post</div><i id="search-trigger" class="fas fa-search fa-fw"></i> <span id="search-wrapper" class="align-items-center"> <i class="fas fa-search fa-fw"></i> <input class="form-control" id="search-input" type="search" aria-label="search" autocomplete="off" placeholder="Search..."> </span> <span id="search-cancel" >Cancel</span></div></div><div id="main-wrapper" class="d-flex justify-content-center"><div id="main" class="container pl-xl-4 pr-xl-4"><div class="row"><div id="core-wrapper" class="col-12 col-lg-11 col-xl-9 pr-xl-4"><div class="post pl-1 pr-1 pl-md-2 pr-md-2"><h1 data-toc-skip>EGFR Targeted Fluorescence Imaging in Gliomas</h1><div class="post-meta text-muted"> <span> Posted <em class="" data-ts="1262278800" data-df="ll" data-toggle="tooltip" data-placement="bottom"> Dec 31, 2009 </em> </span> <span> Updated <em class="" data-ts="1680851732" data-df="ll" data-toggle="tooltip" data-placement="bottom"> Apr 7, 2023 </em> </span><div class="d-flex justify-content-between"> <span> By <em> <a href="">Harish Poptani PhD</a> </em> </span><div> <span class="readtime" data-toggle="tooltip" data-placement="bottom" title="1063 words"> <em>5 min</em> read</span></div></div></div><div class="post-content"><p>Glioblastomas are among the most common malignancies of the brain, with a median survival time of &lt;18 months after initial diagnosis. These tumors are highly invasive in nature and typically infiltrate along the white matter tracts. Anatomic imaging modalities including contrast-enhanced computed tomography and magnetic resonance imaging (MRI) are used extensively for the diagnosis of intracranial neoplasms. However, infiltrative tumor cells (beyond the areas of contrast enhancement) and certain pediatric brain tumors grow in a diffused pattern and do not exhibit contrast enhancement, thereby limiting the use of these imaging modalities. Over the past several years, advanced imaging methods that probe tumor metabolism (magnetic resonance spectroscopy ) or neovascularity (cerebral blood volume ) have been added to clinical imaging routines for increasing the diagnostic efficacy. However, these methods suffer from relatively poor sensitivity and lack the specificity of detecting changes at cellular level. Molecular MRI techniques using targeted contrast agents have recently been proposed to specifically target the tumor cells (see Delikatny and Poptani and references therein). However, these methods are still in their infancy and are limited to poor sensitivity inherent to MRI methods.</p><p>Optical imaging with molecularly targeted imaging agents, on the other hand, promises to have very high degrees of sensitivity and specificity in detection of smaller tumors . The technique is minimally invasive, easy to use, and cost effective and can thus be incorporated at any clinical research institution. The two essential components of optical imaging are the presence of a molecular-specific signal and a system that can detect this signal. The molecular-specific signal is typically generated by the activation of cell-specific proteins, peptides, or genes using an activable contrast agent that can enhance the optical signal from disease-specific molecular markers . Epidermal growth factor (EGF) is one such candidate marker that has been extensively used for the development of targeted contrast agents. Several tumors overexpress the EGF receptor (EGFR), and thus EGF agents that bind to EGFR are commonly used for cancer detection in preclinical tumor models . It has been reported that about 40% to 50% of glioblastomas overexpress EGFR , and thus fluorescence imaging methods can be devised for detection of these tumors. Inhibition of the EGFR pathways has also emerged as a primary mode of anticancer treatment . Currently, four EGFR tyrosine kinase inhibitors are in different stages of clinical development . Among these inhibitors, the monoclonal antibody cetuximab is currently approved for the treatment of head and neck cancer, and early phase clinical trials are in progress for its use in the treatment of brain tumors.</p><p>The work by Gibbs-Strauss et al in this issue of <em>Academic Radiology</em> describes the use of EGFR-targeted fluorescent transmission spectroscopy for the detection of EGFR overexpressing U251 tumors implanted intracranially in the mouse brain. Because of the diffused growth pattern and smaller size of the U251 tumors, the authors were unable to detect these tumors using MRI. However, with EGF-targeted fluorescence imaging, these tumors were detected with 100% sensitivity and specificity. These findings are of particular interest because optical imaging methods could then be used to detect small clusters of metastatic tumor cells or invasive tumor cells beyond the contrast-enhanced area seen on magnetic resonance images. These findings further justify the use of intraoperative fluorescence in the detection of accurate tumor margins, as reported earlier . Gibbs-Strauss et al further report a significant decrease in fluorescence uptake in EGFR-positive U251 tumors after treatment with cetuximab in comparison to untreated controls or EGFR-negative 9L tumors. Glioblastomas in general respond poorly to conventional radiation and chemotherapeutic regimens, and a positive response to cetuximab in tumors overexpressing EGFR may further help in better selection of patients for immunotherapy with cetuximab.</p><p>One of the drawbacks of optical imaging techniques is the poor spatial resolution and limitation to the depth to which the tissue of interest can be observed. Gibbs-Strauss et al used a multichannel transmission fluorescence spectroscopy system and the commercially available EGF-IRDye (LI-COR Biosciences, Lincoln, NE) for detection of the EGF signal from the tumors. It was previously reported by these investigators that the eight–fiber optic probe configuration was better than the two–fiber optic probe configuration in the detection of EGFR-positive tumors . Although technical challenges remain in acquiring better spatial resolution images with optical imaging techniques, the higher specificity to molecular events and the low cost of these techniques make them suitable as complementary tools in the diagnosis and treatment monitoring of brain tumors.</p><h2 id="references"><span class="mr-2">References</span><a href="#references" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><ul><li><p>1. Hollingworth W., Medina L.S., Lenkinski R.E., et. al.: A systematic literature review of magnetic resonance spectroscopy for the characterization of brain tumors. AJNR Am J Neuroradiol 2006; 27: pp. 1404-1411.</p><li><p>2. Chawla S., Poptani H., Melhem E.R.: Anatomic, physiologic and metabolic imaging in neuro-oncology. Cancer Treat Res 2008; 143: pp. 3-42.</p><li><p>3. Delikatny E.J., Poptani H.: MR techniques for in vivo molecular and cellular imaging. Radiol Clin North Am 2005; 43: pp. 205-220.</p><li><p>4. Shah K., Weissleder R.: Molecular optical imaging: applications leading to the development of present day therapeutics. NeuroRx 2005; 2: pp. 215-225.</p><li><p>5. Kumar S., Richards-Kortum R.: Optical molecular imaging agents for cancer diagnostics and therapeutics. Nanomedicine 2006; 1: pp. 23-30.</p><li><p>6. Ke S., Wen X., Gurfinkel M., et. al.: Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts. Cancer Res 2003; 63: pp. 7870-7875.</p><li><p>7. Mischel P.S., Cloughesy T.F.: Targeted molecular therapy of GBM. Brain Pathol 2003; 13: pp. 52-61.</p><li><p>8. Kim E.S., Kies M., Herbst R.S.: Novel therapeutics for head and neck cancer. Curr Opin Oncol 2002; 14: pp. 334-342.</p><li><p>9. Matter A.: Tumor angiogenesis as a therapeutic target. Drug Discov Today 2001; 6: pp. 1005-1024.</p><li><p>10. Wood J.M., Bold G., Buchdunger E., et. al.: PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000; 60: pp. 2178-2189.</p><li><p>11. Gibbs-Strauss S.L., Samkoe K.S., O’Hara J.A., et. al.: Detecting epidermal growth factor receptor tumor activity in vivo during cetuximab therapy in murine gliomas. Acad Radiol 2010; 17: pp. 7-17.</p><li><p>12. Asgari S., Rohrborn H.J., Engelhorn T., Stolke D.: Intra-operative characterization of gliomas by near-infrared spectroscopy: possible association with prognosis. Acta Neurochirurgica 2003; 145: pp. 453-460.</p><li><p>13. Gibbs-Strauss S.L., O’Hara J.A., Srinivasan S., Hoopes P.J., Hasan T., Pogue B.W.: Diagnostic detection of diffuse glioma tumors in vivo with molecular fluorescent probe-based transmission spectroscopy. Med Phys 2009; 36: pp. 974-983.</p></ul></div><div class="post-tail-wrapper text-muted"><div class="post-meta mb-3"> <i class="far fa-folder-open fa-fw mr-1"></i> <a href='/categories/academic-radiology/'>Academic Radiology</a>, <a href='/categories/volume-17/'>Volume 17</a>, <a href='/categories/issue-1/'>Issue 1</a></div><div class="post-tags"> <i class="fa fa-tags fa-fw mr-1"></i> <a href="/tags/journals/" class="post-tag no-text-decoration" >Journals</a> <a href="/tags/general-radiology/" class="post-tag no-text-decoration" >General Radiology</a></div><div class="post-tail-bottom d-flex justify-content-between align-items-center mt-3 pt-5 pb-2"><div class="license-wrapper"> This post is licensed under <a href="https://creativecommons.org/licenses/by/4.0/"> CC BY 4.0 </a> by the author.</div><div class="share-wrapper"> <span class="share-label text-muted mr-1">Share</span> <span class="share-icons"> <a href="https://twitter.com/intent/tweet?text=EGFR%20Targeted%20Fluorescence%20Imaging%20in%20Gliomas%20-%20Radiology%20Tree&url=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fegfr-targeted-fluorescence-imaging-in-gliomas%2F" data-toggle="tooltip" data-placement="top" title="Twitter" target="_blank" rel="noopener" aria-label="Twitter"> <i class="fa-fw fab fa-twitter"></i> </a> <a href="https://www.facebook.com/sharer/sharer.php?title=EGFR%20Targeted%20Fluorescence%20Imaging%20in%20Gliomas%20-%20Radiology%20Tree&u=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fegfr-targeted-fluorescence-imaging-in-gliomas%2F" data-toggle="tooltip" data-placement="top" title="Facebook" target="_blank" rel="noopener" aria-label="Facebook"> <i class="fa-fw fab fa-facebook-square"></i> </a> <a href="https://t.me/share/url?url=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fegfr-targeted-fluorescence-imaging-in-gliomas%2F&text=EGFR%20Targeted%20Fluorescence%20Imaging%20in%20Gliomas%20-%20Radiology%20Tree" data-toggle="tooltip" data-placement="top" title="Telegram" target="_blank" rel="noopener" aria-label="Telegram"> <i class="fa-fw fab fa-telegram"></i> </a> <i id="copy-link" class="fa-fw fas fa-link small" data-toggle="tooltip" data-placement="top" title="Copy link" data-title-succeed="Link copied successfully!"> </i> </span></div></div></div></div></div><div id="panel-wrapper" class="col-xl-3 pl-2 text-muted"><div class="access"><div id="access-lastmod" class="post"><div class="panel-heading">Recently Updated</div><ul class="post-content pl-0 pb-1 ml-1 mt-2"><li><a href="/posts/neurometabolites-alteration-in-the-acute-phase-of-mild-traumatic-brain-injury-mtbi/">Neurometabolites Alteration in the Acute Phase of Mild Traumatic Brain Injury (mTBI)</a><li><a href="/posts/reinforcing-the-importance-and-feasibility-of-implementing-a-low-dose-protocol-for-ct-guided-biopsie/">Reinforcing the Importance and Feasibility of Implementing a Low-dose Protocol for CT-guided Biopsies</a><li><a href="/posts/rethinking-the-pgy-1-basic-clinical-year/">Rethinking the PGY-1 Basic Clinical Year</a><li><a href="/posts/single-injection-dual-phase-cone-beam-ct-dp-cbct-vascular-anatomy-assessment-and-occult-nodule-det/">Single Injection Dual-Phase Cone Beam CT (DP-CBCT) Vascular Anatomy Assessment and Occult Nodule Detection; Have We Reached the Focus?</a><li><a href="/posts/the-yellow-scale-is-superior-to-the-gray-scale-for-detecting-acute-ischemic-stroke-on-a-monitor-disp/">The Yellow Scale Is Superior to the Gray Scale for Detecting Acute Ischemic Stroke on a Monitor Display in Computed Tomography</a></ul></div><div id="access-tags"><div class="panel-heading">Trending Tags</div><div class="d-flex flex-wrap mt-3 mb-1 mr-3"> <a class="post-tag" href="/tags/general-radiology/">General Radiology</a> <a class="post-tag" href="/tags/journals/">Journals</a></div></div></div><div id="toc-wrapper" class="pl-0 pr-4 mb-5"><div class="panel-heading pl-3 pt-2 mb-2">Contents</div><nav id="toc"></nav></div><script src="https://cdn.jsdelivr.net/npm/tocbot@4.20.1/dist/tocbot.min.js"></script></div></div><div class="row"><div id="tail-wrapper" class="col-12 col-lg-11 col-xl-9 pl-3 pr-3 pr-xl-4 mt-5"><div id="related-posts" class="mb-2 mb-sm-4"><h3 class="pt-2 mb-4 ml-1" data-toc-skip>Further Reading</h3><div class="card-deck mb-4"><div class="card"> <a href="/posts/automatic-identification-of-the-reference-system-based-on-the-fourth-ventricular-landmarks-in-t1-wei/"><div class="card-body"> <em class="small" data-ts="1262278800" data-df="ll" > Dec 31, 2009 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Automatic Identification of the Reference System Based on the Fourth Ventricular Landmarks in T1-weighted MR Images</h3><div class="text-muted small"><p> Rationale and Objectives The reference system based on the fourth ventricular landmarks (including the fastigial point and ventricular floor plane) is used in medical image analysis of the brain s...</p></div></div></a></div><div class="card"> <a href="/posts/cerebral-cavernous-hemangiomas-at-7-tesla/"><div class="card-body"> <em class="small" data-ts="1262278800" data-df="ll" > Dec 31, 2009 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Cerebral Cavernous Hemangiomas at 7 Tesla</h3><div class="text-muted small"><p> Rationale and Objectives Cavernous malformations (cavernomas) occur in 0.4%–0.9% of the population. The most common symptoms of cavernous malformations are seizures. An improved detection of small...</p></div></div></a></div><div class="card"> <a href="/posts/comparison-of-2d-and-3d-views-for-evaluation-of-flat-lesions-in-ct-colonography/"><div class="card-body"> <em class="small" data-ts="1262278800" data-df="ll" > Dec 31, 2009 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Comparison of 2D and 3D Views for Evaluation of Flat Lesions in CT Colonography</h3><div class="text-muted small"><p> Rationale and Objectives Flat lesions in the colon may result in false-negative computed tomography colonography interpretations. It is unknown whether flat lesions are better measured on two-dime...</p></div></div></a></div></div></div><div class="post-navigation d-flex justify-content-between"> <a href="/posts/effect-of-team-training-on-patients-ability-to-complete-mri-examinations/" class="btn btn-outline-primary" prompt="Older"><p>Effect of Team Training on Patients' Ability to Complete MRI Examinations</p></a> <a href="/posts/goals-and-objectives-for-an-integrated-graduated-curriculum-in-abdominal-radiology/" class="btn btn-outline-primary" prompt="Newer"><p>Goals and Objectives for an Integrated, Graduated Curriculum in Abdominal Radiology</p></a></div></div></div></div><div id="search-result-wrapper" class="d-flex justify-content-center unloaded"><div class="col-12 col-sm-11 post-content"><div id="search-hints"><div id="access-tags"><div class="panel-heading">Trending Tags</div><div class="d-flex flex-wrap mt-3 mb-1 mr-3"> <a class="post-tag" href="/tags/general-radiology/">General Radiology</a> <a class="post-tag" href="/tags/journals/">Journals</a></div></div></div><div id="search-results" class="d-flex flex-wrap justify-content-center text-muted mt-3"></div></div></div></div><footer><div class="container pl-lg-4 pr-lg-4"><div class="d-flex justify-content-between align-items-center text-muted ml-md-3 mr-md-3"><div class="footer-left"><p class="mb-0"> © 2023 <a href="https://twitter.com/username">Clinical Team</a>. <span data-toggle="tooltip" data-placement="top" title="Except where otherwise noted, the blog posts on this site are licensed under the Creative Commons Attribution 4.0 International (CC BY 4.0) License by the author.">Some rights reserved.</span></p></div><div class="footer-right"><p class="mb-0">Using the <a href="https://jekyllrb.com" target="_blank" rel="noopener">Jekyll</a> theme <a href="https://github.com/cotes2020/jekyll-theme-chirpy" target="_blank" rel="noopener">Chirpy</a>.</p></div></div></div></footer><div id="mask"></div><a id="back-to-top" href="#" aria-label="back-to-top" class="btn btn-lg btn-box-shadow" role="button"> <i class="fas fa-angle-up"></i> </a><div id="notification" class="toast" role="alert" aria-live="assertive" aria-atomic="true" data-animation="true" data-autohide="false"><div class="toast-header"> <button type="button" class="ml-2 ml-auto close" data-dismiss="toast" aria-label="Close"> <span aria-hidden="true">&times;</span> </button></div><div class="toast-body text-center pt-0"><p class="pl-2 pr-2 mb-3">A new version of content is available.</p><button type="button" class="btn btn-primary" aria-label="Update"> Update </button></div></div><script src="https://cdn.jsdelivr.net/npm/simple-jekyll-search@1.10.0/dest/simple-jekyll-search.min.js"></script> <script> SimpleJekyllSearch({ searchInput: document.getElementById('search-input'), resultsContainer: document.getElementById('search-results'), json: '/assets/js/data/search.json', searchResultTemplate: '<div class="pl-1 pr-1 pl-sm-2 pr-sm-2 pl-lg-4 pr-lg-4 pl-xl-0 pr-xl-0"> <a href="{url}">{title}</a><div class="post-meta d-flex flex-column flex-sm-row text-muted mt-1 mb-1"> {categories} {tags}</div><p>{snippet}</p></div>', noResultsText: '<p class="mt-5">Oops! No results found.</p>', templateMiddleware: function(prop, value, template) { if (prop === 'categories') { if (value === '') { return `${value}`; } else { return `<div class="mr-sm-4"><i class="far fa-folder fa-fw"></i>${value}</div>`; } } if (prop === 'tags') { if (value === '') { return `${value}`; } else { return `<div><i class="fa fa-tag fa-fw"></i>${value}</div>`; } } } }); </script> <script src="https://cdn.jsdelivr.net/combine/npm/magnific-popup@1.1.0/dist/jquery.magnific-popup.min.js,npm/lazysizes@5.3.2/lazysizes.min.js,npm/clipboard@2.0.11/dist/clipboard.min.js"></script> <script src="https://cdn.jsdelivr.net/combine/npm/dayjs@1.11.6/dayjs.min.js,npm/dayjs@1.11.6/locale/en.min.js,npm/dayjs@1.11.6/plugin/relativeTime.min.js,npm/dayjs@1.11.6/plugin/localizedFormat.min.js"></script> <script defer src="/assets/js/dist/post.min.js"></script> <script src="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/js/bootstrap.bundle.min.js"></script> <script defer src="/app.js"></script> <script defer src="https://www.googletagmanager.com/gtag/js?id=G-L66SLQK23K"></script> <script> document.addEventListener("DOMContentLoaded", function(event) { window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-L66SLQK23K'); }); </script>
